Active Implantable Medical Devices Market Size, Share, Growth, Trends, and Forecast 2030

Table Of Content

Methodology

Free Analysis

Implantable medical devices are the type of medical devices that are partially or totally inserted into the human body with the help of medical intervention and are dedicated to remaining there after the procedure. They can support the damaged part, can replace the missing part of the human body or also modify the important function of the body.

According to the WHO (World Health Organization), around 17 million people die annually from cardiovascular diseases. According to the CDC (Centers for Disease Control and Prevention), in 2017, 2.7 to 6.1 million people were suffering from atrial fibrillation, a type of heart arrhythmia, in the U.S. Prevalence of neurological disorders such as epilepsy, Parkinson’s disease, and essential tremors, were reported to be high in emerging economies such as India. For instance, in the U.S. according to NIH (National Institute of Health), approximately 50,000 people suffer from Parkinson’s disease annually. This increase in the prevalence of cardiovascular diseases and neurological disorders has a positive impact on the growth of the global active implantable medical devices market. The high cost of implantable devices and the risks associated with the use of these devices is affecting the growth of the global market for active implantable medical devices.

The active implantable medical devices market is segmented on the product, application, and end-user. Based on the product, the active implantable medical devices market is further segmented into cardiac pacemakers, implantable cardioverter defibrillators (ICD), nerve stimulators, cochlear implants, and ventricular assist devices. The cardiac pacemakers segment is further sub-segmented into single chamber pacemakers, dual chambers pacemakers, and others. Transvenous ICD and subcutaneous ICD are included in the implantable cardioverter defibrillators segment. Nerve stimulators segment includes deep brain stimulators, vagus nerve stimulators, sacral nerve stimulators, gastric electrical stimulators, and spinal cord stimulators. Implantable cardioverter defibrillator (ICD) is anticipated to dominate the market owing to the rapid development of advanced devices. Based on the application, the active implantable medical devices market is sub-segmented into cardiovascular, neurological, hearing impairment, and others. The cardiovascular segment is projected to dominate the active implantable medical devices market in the forecast period. The end-user segment of the active implantable medical devices market includes hospitals, specialty clinics, and ASCs. The hospital segment is expected to dominate the end-user segment due to the presence of a large patient pool in the hospitals. 

North America is anticipated to dominate the market in the forecast period due to the rise in the number of people suffering from arrhythmia and the early launch of technologically advanced products by companies in this region. In the forecast period, Asia Pacific is expected to follow North America and Europe due to an increase in the occurrence of cardiovascular diseases and arrhythmia because of the changing lifestyle and adoption of western culture. Also, the increase in investments and product launches by various companies and less stringent laws regarding implantable devices is expected to fuel the growth of the active implantable medical devices market.

The key players in the global market for active implantable medical devices are Boston Scientific Corp., Cochlear Ltd., LivaNova Plc., Medtronic Plc, Sonova Holding AG, Abbott Laboratories, Nurotron Biotechnology Co. Ltd., William Demant Holding A/S, MED-EL, and Biotronik SE. The company focuses on merger and acquisitions to develop new products with advanced technologies. For instance, in 2015, Cyberonics and Sorin Group merged to form LivaNova Plc. In April 2018, the subsidiaries of Terumo Corp. merged to expand its presence in the global aortic and vascular implants market.